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Coping with Unresolvable Uncertainty: A Situational Analysis of Regenerative Medicine 
Venturing Activity 
 
 
 
 
 
 
 
Abstract 
Acquiring resources, such as knowledge, is a fundamental entrepreneurial task during venture 
development. However, high levels of uncertainty challenge resource identification and access, 
hence collaboration and knowledge exchange mechanisms are valuable. During high levels of 
perceived environmental uncertainty, entrepreneurs and new ventures are required to develop 
coping strategies to ensure venture formation and growth. Yet, entrepreneurial coping during 
high uncertainty is an understudied process. The regenerative medicine (RM) sector represents a 
unique context for studying entrepreneurial activity under high levels of uncertainty. We consider 
how uncertainty in RM venturing affects entrepreneurial behavior. Informed by long-form, 
narrative interviews, we propose a process model of RM venturing linking uncertainty, university 
culture, collaboration and coping. The use of selective revealing in RM venturing, and the effect 
of different coping responses on resource assembly and collaborative knowledge, is considered. 
Our findings advance theories of venture development during high uncertainty.  
 
Keywords: uncertainty, coping, collaboration, knowledge, venturing, entrepreneur  
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Introduction 
In high uncertainty environments, entrepreneurs struggle to identify which resources to 
assemble and coordinate (Alvarez and Barney, 2005). New ventures must acquire key resources 
such as finance, knowledge and partnerships (Jarillo, 1989), but high levels of perceived 
environmental uncertainty (PEU) inhibit entrepreneurial behavior and sense making (Milliken, 
1987). As such, collaboration and knowledge exchange mechanisms become especially valuable 
for the development of deep capabilities needed to exploit opportunities (Powell et al, 1996; 
George et al, 2008). When PEU is high, entrepreneurs and ventures must develop coping 
mechanisms to avoid paralysis and ensure venture formation and growth. Despite important 
implications for theories of entrepreneurial behavior and venture growth, the development of 
entrepreneurial coping strategies under high uncertainty has not been rigorously studied. 
The regenerative medicine (RM) sector represents a fruitful context for studying 
entrepreneurial activity under extremely high levels of PEU. RM research, which often involves 
the use of stem cells, is “the process of creating living, functional tissues to repair or replace 
tissue or organ function lost due to age, disease, damage or congenital defects” (NIH, 2006). 
RM is expected to address unmet clinical needs, enhance human health, and generate significant 
commercial benefits. However, extremely high levels of uncertainty have limited the 
development of the RM industry. Despite active research clusters in numerous geographic 
locations, including the UK (Jennifer, 2011), venturing has been slow and the venturing process 
unclear.  
Venture development in RM has not been well studied. We study how uncertainty affects 
entrepreneurial behavior through a situational analysis of resource assembly in RM venturing 
activity. In particular, we ask two questions. First, what are the unique aspects of resource 
assembly in RM venturing? Second, how does knowledge, accessed through collaborations and 
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networks, affect RM venture formation and growth? Informed by a pilot survey and long-form 
narrative interviews, we propose a RM venturing process model. The results point towards the 
development of specific coping strategies to address high levels of PEU. These are linked to the 
development of collaborative knowledge during venture formation and growth. Our study opens 
new research directions linking entrepreneurial sense-making to venture growth when uncertainty 
cannot be resolved by information gathering or analysis. It specifically builds on recent 
investigations on selective revealing as an alterative form of collaboration (Alexy et al, 2013). 
 
Contributions 
This research makes three contributions to the scholarly literature. First, we investigate 
entrepreneurial activity in an understudied field characterized by unusually high uncertainty. 
Second, this study advances theories of venture development by proposing a preliminary model 
linking uncertainty, collaboration and coping. Third, we extend university-industry scholarship 
by showing the link between university culture and venture coping strategies.  
Our research also provides important practical contributions to RM practitioners and 
technology transfer offices (TTOs). 
 
Venturing in the Regenerative Medicine Field 
The RM industry faces complex political and social forces, uncertain regulatory 
frameworks, unresolved intellectual property (IP) rights issues, and untested production and 
distribution systems (Hogle, forthcoming 2014). The investment and infrastructure requirements 
of RM commercialization have favored entrepreneurial activities with explicit links to university 
research programs. These ties, along with the complex technological innovations of RM research 
and the uncertain venturing process, create numerous development challenges for RM 
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entrepreneurs. 
The dependency on the larger institution may create resource assembly challenges for new 
technology ventures (Powell et al, 1996). These firms must operate with little or no slack in their 
resource pool, limiting product-market and business model exploration and testing (George, 
2005; Bock et al, 2012). The perception of high risk in RM venturing has limited investments by 
venture capitalists (VCs) and pharmaceutical companies. This has created a capabilities gap 
between RM innovation and commercialization (Mittra and Tait, 2012). Entrepreneurs may 
compensate for resource scarcity by accessing social networks to legitimize organizational 
narratives and access knowledge and financial resources (Aldrich and Martinez, 2001; Lounsbury 
and Glynn, 2001). We expect that RM entrepreneurs and ventures will rely on collaboration and 
networks to access resources, including knowledge, in order to exploit opportunities. The 
processes, however, have not been carefully investigated within the context of RM venturing 
activity. 
 
Methods 
To explore sense-making and behavioral processes, we utilize a primarily qualitative 
approach to better develop insights into socially constructed knowledge and events (Locke, 
2001). A small pilot survey confirmed the relevance of key constructs, but the primary dataset 
consists of long-form, narrative interviews (McCracken, 1988).  
 
Data  
Information about the complete set of qualitative informants is provided in Table 1. This 
includes role, informant type, organizational affiliation and location. 
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--------------------------------- 
Table 1 here 
--------------------------------- 
The lead author conducted face-to-face, long-form narrative interviews with informants 
between November 2012 and September 2013. Interviews were conducted in private facilities to 
prevent interruptions and ensure confidentiality. Informants were asked to tell their story of their 
participation in the commercialization of regenerative medicine innovation. Informants were 
given complete freedom to recount their narrative without interruption and with limited or no 
further direction. This narrative interview approach was utilized to minimize investigator bias, 
increase informant comfort and encourage informants to recount their own story in their own 
words, allowing them to focus on self-identified areas of interest. Legal and ethical controversies 
associated with RM require an especially sensitive approach to the collection of qualitative data. 
The open-ended, non-directed narrative approach helps to reduce staged responses and social 
desirability bias (Podsakoff et al, 2003). Informants were encouraged to talk until they felt that 
they had reached a self-determined conclusion. Following the informant-determined end of the 
main narrative, some informants were prompted to provide additional details on key areas of 
interest. Field notes were generated during and immediately after each interview to provide in 
situ interpretation to complement transcript coding. The duration of the interviews ranged from 
16 minutes to 111 minutes, with the average length being approximately 60 minutes.  
A small-scale pilot survey was utilized to confirm the relevance of key constructs and 
frame the coding of the narrative interviews. The survey was designed to elicit data on 
informant’s perceptions of RM venturing. Survey questions included both closed and open-ended 
questions on facilitative and inhibitive factors to RM venturing activity. Question types and order 
were carefully considered to reduce common method biases (Podsakoff et al, 2003). The survey 
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was pre-tested by administration to an RM industry expert and an academic scientist to ensure 
clarity of design and relevance of the questions (Fowler, 2009).  
The lead author obtained information on target informants from Edinburgh BioQuarter, the 
commercialization arm of research output from the College of Medicine and Veterinary Medicine 
at The University of Edinburgh. Informants were selected based on direct involvement in the 
commercialization of RM in one of the following 4 categories: 1) RM entrepreneurs, 2) academic 
scientists, 3) RM/life science support entities, 4) RM companies. We excluded for-profit third 
party support firms such as consultancies. We also excluded full-time students, even those with 
significant entrepreneurial intent. This ensured efficient and effective saturation of categories, 
providing sufficient data to account for all aspects of the phenomenon (Morse et al, 2002). 
Informants were not provided detailed information about the interview to prevent prejudicial 
preparation of information or materials. The final dataset includes 23 long-form narratives. 
 
Procedures  
Coding of the qualitative interviews was informed by the results of the pilot survey. Survey 
informants were selected from the RM informant target list and e-mailed regarding their 
participation. We invited 26 individuals to participate in the survey and received 15 responses, 
which represents a 58% success rate. Referrals by first-wave respondents to additional industry 
participants generated 7 additional responses. Therefore, a total of 22 responses were utilized in 
the pilot survey analysis. Since the pilot survey data was used primarily to inform the qualitative 
interview coding, we report only simple descriptive statistics.  
Analysis of the RM venturing interview narratives was informed by grounded theory 
(Strauss and Corbin, 1990). First-order codes were generated via open-ended coding of the 
transcripts. These were triangulated against the results of the pilot survey to identify overlap and 
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gaps. Then, through a cycle of inductive and deductive reasoning, theoretical categories 
representing theoretical groupings of the first-order codes were identified. Finally, theoretical 
categories were organized into aggregate theoretical dimensions.  
 
Findings 
We first present the findings of the online pilot survey. Following this, we discuss the 
narrative interview findings. 
 
Online pilot survey findings 
Pilot survey findings are presented in Figure 1. Most informants agreed (45.45%) or 
strongly agreed (31.82%) that RM commercialization is challenging due to resource constraints, 
and that collaborations are required for commercialization. Informants agreed (45.45%) or 
strongly agreed (27.27%) that collaboration with academic institutions is a requirement for 
commercialization. Similarly, most informants agreed (40.91%) or strongly agreed (36.36%) that 
collaboration with hospitals is necessary for commercialization. However, the majority of 
informants disagreed (50.00%) that collaborations with “big pharma” (large pharmaceutical 
companies) are required for RM commercialization. Most informants agreed (45.45%) that 
collaborations provide RM ventures with access to resources and agreed (63.64%) that 
collaborations enabled capabilities to be acquired. Furthermore, informants agreed (54.55%) or 
strongly agreed (36.36%) that knowledge is exchanged during collaborations and disagreed 
(40.91%) with the statement that RM collaborations were difficult to manage. Informants also 
disagreed (36.36%) or neither agreed/disagreed (31.82%) that RM collaborations often fail to 
deliver. Most informants agreed (31.82%) that governmental funding could be accessed for 
commercialization. However, there were differing views as to whether VC funding could be 
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accessed, with 31.82% of informants being in agreement and 31.82% being in disagreement. 
There was high agreement (63.64%) amongst informants that unresolved regulatory issues are 
affecting RM commercialization. Also, most informants agreed (36.36%) that manufacturing, 
distribution and scale-up uncertainties are affecting RM commercialization. Most informants 
agreed (40.91%) that unrealistic timeframes are set for RM commercialization, and most agreed 
(31.82%) or strongly agreed (31.82%) that RM business models are unknown and unproven. 
--------------------------------- 
Figure 1 here 
--------------------------------- 
Narrative interview findings 
Output of the interview findings is presented in Table 2, utilizing a multi-level data 
structure (Walsh and Bartunek, 2011). The first column of the table shows the prevalence (%) of 
first-order codes within the total (T) 23 interviews. The table also highlights the prevalence (%) 
of first-order codes for each category, which includes interviews with 6 entrepreneurs (E), 
interviews with 3 academics (A), interviews with 12 support entities (SE) and interviews with 2 
RM companies (RC). We provide further discussion on first-order codes, theoretical categories 
and theoretical dimensions. Illustrative examples of first-order codes and theoretical categories 
are presented in Table 3. 
--------------------------------- 
Table 2 here 
--------------------------------- 
We review the theoretical dimensions revealed by the data and note specific examples to 
highlight findings and relevance. 
 
Perceived environmental uncertainty (PEU). Our data shows high levels of PEU 
surrounding RM venturing. In consideration of Milliken’s (1987) typology of uncertainty, RM 
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ventures face high levels of state, effect and response uncertainties. In particular, given the high 
levels of environmental unpredictability, RM ventures face higher levels of state uncertainty. 
Informants consistently reported high levels of funding uncertainties, discussing the difficulties in 
securing funding for commercialization purposes. This is illustrated in example A in Table 3. RM 
venturing requires this funding gap or “valley of death” between stem cell discovery and 
translation to be bridged. Yet, achieving this is problematic at present, since RM venturing 
generally exceeds current investor timeframes and investment limits. Nevertheless, example B 
illustrates how conditional approval could be implemented in order to ease the funding gap. This 
provides ventures with access to the market prior to obtaining comprehensive data on safety and 
efficacy, but with the provision that more data is provided in the near future.  
High levels of uncertainty also surround manufacturing, scale-up and distribution, as 
highlighted in example C. This is consistent with prior research conducted on RM business 
models, which highlighted the problems faced by a bio-artificial liver device venture in 
distributing their product due to unavailable cryogenic solutions (Mastroeni et al, 2012). As such, 
we see in example D that to overcome distribution uncertainties, more localized RM treatments 
will be required where the patient travels to the site of production. 
RM ventures also face high levels of regulatory uncertainty, especially unresolved IP rights 
issues, which is illustrated in example E. Legislative changes regarding the use of human 
embryonic stem cells (hESCs) has resulted in the shift to induced pluripotent stem cells (iPSC) 
but has required ventures to adapt their business model as a consequence. Whilst iPSC are seen 
as being more ethically acceptable, ethical uncertainties still surround the RM sector. 
Furthermore, scientific shifts are likely because stem cell science is still in its infancy.  
It would appear that ventures focusing on tools or diagnostics are the most viable. This is 
because the financial resources required for commercialization of tools or diagnostics is 
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significantly lower than the financial resources required to commercialize therapeutics. Example 
F in Table 3 illustrates this. However, despite tools or diagnostic ventures being the most viable 
in the short-term, given the current uncertainty within the RM sector, young RM tools or 
diagnostic ventures are likely to face downstream uncertainties such as reimbursement 
uncertainties, as confirmed in example G. 
Coupled with these uncertainties are high levels of risk, which results in investor 
skepticism (Giebel, 2005). Risk was consistently discussed, with the suggestion that China and 
the US has different perceptions of risk in comparison to the UK. In a slightly different context, 
entrepreneurs discussed risk in terms of the personal risk that they face in financing their venture, 
as illustrated in example H. In contrast, when financial resources were obtained through 
governmental bodies, without this funding having to be matched or offered on a loan basis, risk 
was mitigated for the entrepreneur or venture.  
Many of the uncertainties discussed within the dataset are consistent with previous research 
(Plagnol et al, 2009). It is evident that some ventures are not fully committing to this sector and 
only deploying limited resources until uncertainty and risk are reduced. Therefore, if the sector is 
to see advancements in RM venturing, these uncertainties must be addressed. In achieving this, 
RM ventures are engaging in collaborations, legitimacy building and knowledge exchange 
mechanisms. 
 
University entrepreneurial culture. RM venturing is primarily driven by university-led 
stem cell research. As such, university academic scientists may be expected to participate in 
commercialization activities. This requires the inventing entrepreneur to modify their role-
identity, shifting from a scientific orientation to a more market-driven approach (Jain et al, 2009). 
However, as illustrated in example I, this often creates conflicting pressures as academics are 
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measured on research papers and grants, not commercialization outcomes. This tension could 
impact their motivation for commercialization (Ndonzuau et al, 2002; Etzkowitz, 1998).  
Commercialization of university-led stem cell innovations will be influenced by the 
entrepreneurial culture embedded within the university and the TTO’s policies and procedures 
(Degroof and Roberts, 2004; Di Gregorio and Shane, 2003). Clear TTO policies may enable 
greater levels of commercialization (Lockett et al, 2003). Policies rewarding academic 
entrepreneurial behavior and commercialization have been shown to result in greater levels of 
commercialization (Renault, 2006; Friedman and Silberman, 2003; Lach and Schankerman, 
2004; Henrekson and Rosenberg, 2001). Furthermore, the business development capabilities of 
TTO staff can influence commercialization (Thursby and Kemp, 2002; Lockett and Wright, 
2005). Some staff may lack the technical and entrepreneurial understanding that is required to 
commercialize stem cell science (Lockett et al, 2005), which is highlighted in example J. RM 
venturing will, therefore, ultimately depend on universities deinstitutionalizing their traditional 
academic culture and adopting a more commercially oriented and entrepreneurial one (Scott, 
2001; Dacin et al, 2002).  
 
Coping strategies. In order to address high levels of PEU, entrepreneurs or ventures will 
be required to engage in coping strategies (Milliken, 1987). Our findings show entrepreneurs and 
ventures engaging in collaborations and legitimacy building in order to address the high levels of 
PEU.  
The majority of collaborations are taking place for resource assembly purposes and 
improving particular processes, as highlighted in examples K and L respectively. They also 
provide access to funding and can build the legitimacy of a particular venture. Collaborations 
with industry and academia appear to be the most dominant types of collaboration within the 
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dataset. Collaborations with the National Health Service (NHS) are also vitally important for RM 
venturing, as they enable access to clinicians. However, gaining access to the NHS and forming a 
collaborative partnership is currently challenging, as illustrated in example M. Collaborations 
involving support entities provide ventures with access to executives with expertise in new 
venture development. They also facilitate in connecting ventures with investment communities. 
However, despite the benefits of collaborations, the costs associated with collaborations were 
evident, as shown in example N.  
In addition to the role of collaboration in addressing the high levels of PEU, uncertainty 
reduction is also possible as a consequence of legitimacy building. When high amounts of 
uncertainty and controversy surround a novel technology, legitimization of this technology 
becomes essential and can result in ventures acquiring critical resources (Jain and George, 2007). 
Legitimacy building can be achieved through entrepreneurial narratives, resulting in the creation 
of new wealth (Lounsbury and Glynn, 2001; Martens et al, 2007). Entrepreneurial stories were 
evident within the dataset as a means of legitimacy building and serving to reduce uncertainty, as 
highlighted in example O. To enhance legitimacy ventures should protect their technology, 
widely publicize their technology and influence key stakeholders (Jain et al, 2009). Example P 
highlights the protection of stem cell research. Publicizing technology through raising awareness 
is documented in example Q. The influencing of key stakeholders is illustrated in example R. 
 
Collaborative knowledge. Coping strategies impact on resource assembly and enable the 
access of knowledge for venture formation and growth. Research on absorptive capacity (Cohen 
and Levinthal, 1990; Zahra and George, 2002) and tacit knowledge suggests that the 
sophisticated, technological requirements of life science entrepreneurship make it unlikely that 
new ventures will possess sufficient internal knowledge and must, therefore, collaborate and 
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engage in resource exchange mechanisms to become competitive. Our findings highlight the 
exchange of knowledge and communication between the various actors operating within the RM 
sector. Knowledge is accessed through collaborations and networks, as illustrated in examples S 
and T respectively. This can be especially valuable as it can enable capability development. This 
is supported in example U, where we see knowledge being accessed via collaboration with a 
university in order to develop capabilities. Accessing knowledge through NHS collaborations is 
also shown to be particularly useful, as this can identify relevant disease areas and markets to 
target. This is highlighted in example V. Such knowledge exchange mechanisms can result in 
learning. However, informants did discuss the difficulties in exchanging knowledge due to the 
language differences between the various actors within the sector and due to the tacitness of RM 
knowledge. This is illustrated in example W. 
Social networks have been suggested to be an important mechanism for the assembly of 
resources and in the creation and exchange of knowledge (Aldrich and Martinez, 2001; 
Ardichvili et al, 2002). Within the RM sector there are several life science communities that have 
been established, with the aim of ensuring successful RM venturing. The Scottish Stem Cell 
Network (SSCN) was formed in 2002 and was tasked with building a RM community and 
delivering RM commercialization. This network connected the scientific community and SME 
community, and served to bridge the gap between the different languages spoken by the various 
actors within the RM sector. SSCN closed in January 2012 due to the lack of further 
governmental backing. In its place the Cell Therapy Catapult was formed in London, which is 
funded by the UK government and is charged with growing the UK stem cell sector. This is to be 
achieved through the advancement of RM research and bridging the translational gap, resulting in 
commercialization. In addition, knowledge transfer networks have been established. The Health 
Knowledge Transfer Network is concerned with delivering innovation within the health sector, 
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which includes the medical biotechnology, medical technology, diagnostics and pharmaceutical 
industries. They organize events and workshops where industry actors can meet in order to share 
ideas and gain access to potential collaborators. The network also acts as a facilitator for the 
identification of new sources of funding. In example X we show knowledge access via networks, 
which assists the assembly of financial resources 
 
Venture development. Accessing knowledge through collaborations and networks can 
enable RM ventures to form and grow. During this venture development period, ventures may 
continue to engage in coping strategies, resulting in additional collaborative knowledge. 
However, RM venture development is challenged due to a lack of slack resources. Financial 
resources are fundamental for venture formation and growth (Cassar, 2004), yet our data shows 
that entrepreneurs and ventures struggle to acquire financial resources. Governmental funding 
appears to be available for basic scientific RM research and to progress RM research to phase 
one/two studies. However, access to funding for clinical stage research and to deliver this 
research to market is currently challenging, as illustrated in example Y. At present, entrepreneurs 
and early stage RM ventures are required to match governmental funding with their existing 
financial resources, which is difficult. This is shown in example Z.  
Currently, RM business models are unknown and unproven. Since RM is an evolving 
sector, it is reasonable to expect that RM business models will differ from the dominant life 
science business models and, as a result of the highly uncertain environment, it is probable that 
RM business models may evolve through a trial-and-error process (Heirman and Clarysee, 2004; 
Loch et al, 2008; Costa and Levie, 2012). Business model evolution through trial-and-error was 
exemplified within the dataset. When complexity and uncertainty are high, ventures may run 
multiple parallel business models and select the best performing one (Loch et al, 2008), as 
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illustrated in example AA. This example documents how a RM venture ran two separate business 
models due to the high levels of uncertainty surrounding the sector. One focused on RM services, 
whilst the other focused on a RM tools business model. It transpired that there was not the market 
demand for the service business model and, therefore, the tools business model was adopted. 
Informants also discussed uncertainty surrounding their own business model, in some cases 
discussing business model failure or changes to their current business model due to a lack of 
market demand. This highlights that RM business models cannot be predicted ex ante. 
Entrepreneurs discussed their desire to become players in the RM therapeutics market but due to 
the high uncertainties and costs of being involved in this market, all were prevented from 
operating in this space. However, example BB illustrates a venture that is combining a business 
model focusing on tools with the desire to develop cell-based therapeutics, which hints towards 
business model innovation (George and Bock, 2012). Although, it remains unclear whether this 
venture is truly innovating their business model because business model innovation requires a 
deep understanding of market trends and sufficient resources to direct towards novel 
opportunities (Bock et al, 2012; Johnson et al, 2008). Therefore, it appears from the dataset that 
RM ventures focusing on tools or diagnostics may have a clearer path to a viable business model 
than those focusing on therapeutics, as previously discussed.  
 
Outcomes. Currently the economic impact of the entire RM market is estimated to be 
between $2-5 billion, which is expected to exceed $11 billion by 2020, contributing to a 
substantial reduction in healthcare costs (Tait et al, 2011). University-led RM venturing has the 
potential to result in significant economic gains. However, it should not be forgotten that failure 
is an unavoidable aspect of any entrepreneurial venture and even if universities are successful in 
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transferring their technology, they should not always expect the economic gains to accrue to their 
local area (Miner et al, 2001; Bock, 2012). 
The economic impacts of university-led technology transfer can be significant but 
technologies emanating from the university, most often than not, will require vast amounts of 
investment and time in order to become commercially viable (Bock, 2012). Informants, 
especially RM support entities, were especially concerned with RM venturing positively 
impacting the local economic environment. However, there was some concern as to whether the 
local environment could retain this innovation. Furthermore, the immediate visible economic 
gains for RM are not always apparent, as benefits are not instantaneously observable, which can 
affect investment. Example CC illustrates this. 
Despite the high uncertainty surrounding RM venturing, suggestions for the trajectory of 
the market were forthcoming. One entrepreneur suggested that ventures should collaborate with 
the NHS to enable widespread commercialization. This will provide access to clinicians who are 
best placed to offer suggestions on disease areas and indications. The disease areas to focus on 
should be “orphan” diseases, as taking an orphan drug to market requires less financial capital 
and is less time intensive. As such, orphan drugs could serve as the exemplar to the RM industry, 
providing greater confidence in the market and enabling further investment. Furthermore, NHS 
collaboration provides access to NHS patients and the opportunity for clinical trials to be 
conducted. This can provide gradual safety and efficacy data, and along with conditional 
approval, this could prevent the need for large-scale efficacy trials, which are highly expensive 
and currently hindering RM venturing. Another future scenario, as suggested by an academic 
scientist, views RM venturing initially relying on the use of regenerative tools and technologies 
in drug screening. Over the next ten years, the industry will begin to see bespoke RM therapies as 
processing costs reduce. This could involve cells being taken from a patient, grown up in culture 
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and then introduced back into the patient in order to repair the degenerative tissue or organ. 
Eventually, as we witness more scientific advances in the RM field, there will be widespread use 
of RM therapies for tissue or organ repair.  
Informants also discussed the timeframes involved for RM scientific progression and 
widespread venturing. The expected timeframes for taking RM science to market differs amongst 
the actors operating within the sector. VCs, SMEs and the UK government do not understand the 
timeframes involved in taking RM science to market, according to entrepreneurs and RM support 
entities. VCs, SMEs and the UK government expect a much quicker return on investment and as 
a consequence, this has serious implications for RM funding and, ultimately, commercialization. 
This is illustrated in example DD. A more reasonable timeframe for investors to see a return on 
their investment was suggested to be 10-30 years. In terms of scientific progressions, it was 
suggested that it could be 50 years before there is large-scale use of stem cells. 
--------------------------------- 
Table 3 here 
--------------------------------- 
Our data also highlights differences in the way in which each category of informant 
addresses the high levels of PEU and their approach to RM venturing. We have previously 
shown, in Table 2, the differences in the prevalence (%) of each first-order code between all 4 
categories of informants. To further illustrate the differences between categories and their 
approach to RM venturing, we highlight in Figure 2 the average occurrence (%) of each 
theoretical dimension per informant category. This suggests the formation of two distinct lenses 
in informants’ approach to RM venturing.  
Lens 1 consists of entrepreneurs and RM support entities. Both approach venturing in a 
similar way and have similar perceptions of uncertainty, including the significance and effect of 
uncertainty. Both categories lack slack resources and place more emphasis on the venture 
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development stage of the venturing model. They also both face similar PEU concerns, especially 
in relation to funding uncertainties. However, some differences are visible. For example, 
entrepreneurs appear to be relying on coping strategies less than any other category. Whilst 
further research is required in order to fully understand why this is the situation, we suggest that 
it is likely to be as a result of collaboration costs, which were evident within the dataset for the 
entrepreneur category.  
 Lens 2 consists of academics and support entities. They place a high emphasis on coping 
strategies, particularly collaborations, in addressing high levels of PEU. These collaborations 
progress scientific developments and improve current RM processes. Both categories are 
similarly concerned with the outcomes of RM venturing, especially in terms of innovation and 
economic development. 
--------------------------------- 
Figure 2 here 
-------------------------------- 
Discussion 
Following the findings we present a RM venturing process model. Given the high levels of 
PEU surrounding RM venturing, we discuss alternative collaboration mechanisms. We extend the 
discussion to reflect on the effects of different coping strategies on resource assembly and 
collaborative knowledge. The effect of uncertainty on institutional culture is also considered. 
 
A process model of RM venturing 
Based on our findings we propose a RM venturing process model. This model is presented 
in Figure 3 and shows that high levels of PEU affect RM venturing. Also, since RM venturing is 
driven by university-led stem cell research, the entrepreneurial culture embedded within the 
university will determine successful RM venturing. In an attempt to overcome PEU and ensure 
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successful venturing, RM ventures engage in coping strategies. Coping responses include 
collaborations and legitimacy building, which enables the assembly of resources and 
development of collaborative knowledge, resulting in venture formation and growth. As ventures 
continue to develop they may engage in further coping strategies, resulting in additional 
collaborative knowledge development. The final part of the model is the outcome of the venture, 
which may be a success and lead to economic gains, or it may be a failure. 
--------------------------------- 
Figure 3 here 
--------------------------------- 
Collaboration under unresolved uncertainty 
Our findings indicate that entrepreneurs rely on coping strategies less than any other 
category. We have shown collaborative costs to exist during collaborations and highlighted 
unwilling collaborators. In addition, given the high levels of PEU, high partner uncertainty is 
expected. Under conditions of high collaboration costs, unwilling collaborators and high partner 
uncertainty, it is possible that RM entrepreneurs and new ventures rely on selective revealing as 
an alternative strategic mechanism to known collaboration mechanisms (Alexy et al, 2103). 
Through the selective revealing of knowledge, the focal collaborating firm attempts to induce the 
external collaborating firm to become more similar to them with respect to the production of 
knowledge. However, the use of selective revealing strategies in RM venturing may be 
problematic. If RM entrepreneurs and new ventures lack knowledge, or hold incorrect 
knowledge, we propose that the use of selective revealing in RM venturing will create 
collaborative networks of ignorance. This will have serious implications for the development of 
collaborative knowledge and venture outcome, since opportunity recognition depends on 
individuals mentally comparing new information with prior knowledge through a cognitive 
process of structural alignment (Grégoire et al, 2010). Therefore, if entrepreneurs or new 
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ventures lack knowledge, or if incorrect knowledge has been selectively revealed, opportunity 
recognition will be affected.  
 
Coping strategies: resource assembly and collaborative knowledge  
Coping with uncertainty is a three-staged process. It involves primary appraisal in which 
individuals evaluate the threats to themselves. Secondary appraisal considers the response 
options available in order to deal with these threats. Coping with these threats relies on 
implementing the response options available and involves the use of two coping functions: a 
problem-focused coping and an emotion-focused coping (Lazarus and Folkman, 1984). During 
stressful situations individuals will utilize both types of coping functions in addressing the 
particular problem. However, problem-focused coping tends to predominate when individuals 
perceive that they can address the particular situation and emotion-focused coping prevails when 
the situation is less controllable (Folkman and Lazarus, 1980). 
In this study we have shown that coping strategies include collaborations and legitimacy 
building. These depend on culture and uncertainty, and enable resource assembly and 
collaborative knowledge development. Such coping responses are examples of problem-focused 
coping strategies, as they reduce or remove the high levels of PEU. Several forms of problem-
focused coping have been identified, such as specific interpersonal efforts to alter the stressful 
situation or the seeking of social support (Folkman et al, 1986b). The specific problem-focused 
coping form implemented by entrepreneurs is likely to have differing effects on resource 
assembly and collaborative knowledge development. For example, RM entrepreneurs 
implementing problem-focused coping, in which they seek social support, may find that they are 
unable to assemble resources and develop collaborative knowledge. This is because this form of 
coping relies on entrepreneurs obtaining external advice, assistance or knowledge. Yet, the 
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potential existence of networks of ignorance is likely to result in access to incorrect advice, 
assistance or knowledge. This will have serious implications for venture outcomes. 
Emotion-focused coping strategies enable entrepreneurs to manage their emotions in 
relation to the uncertainty and are most suited to uncontrollable situations. Therefore, they are 
especially valuable to entrepreneurs and ventures during RM venturing due to the high levels of 
unresolvable uncertainty surrounding RM. Several forms of emotion-focused coping strategies 
exist, which can facilitate or inhibit problem-focused coping. These include: wishful thinking, 
distancing, emphasizing the positive, self-blame, tension-reduction and self-isolation (Folkman et 
al, 1986a). Again, we can expect resource assembly and collaborative knowledge development to 
proceed differently depending on which form of emotion-focused coping is adopted. For 
example, entrepreneurs relying on wishful thinking may fail to see potential flaws in their 
business model or RM technology. If they then collaborate for resource assembly and knowledge 
development purposes, homophily effects suggest that the collaborating firm will also fail to see 
the potential flaws. This will have serious consequences on venture formation and growth. 
Similarly, entrepreneurs who rely on distancing themselves from the high levels of PEU, may fail 
to assemble resources and develop collaborative knowledge. 
Individuals differ in their coping responses (Carver et al, 1989) and, therefore, resource 
assembly and collaborative knowledge development will vary. In this study we have shown that 
RM informant categories differ in their coping responses to high levels of PEU. As such, we 
reported two lenses, which consisted of entrepreneurs and ventures in one lens, and academic and 
support entities in another lens. This suggests that there is not an objectively “correct” 
interpretation of the best commercialization path. Unresolvable uncertainty and variations in the 
best commercialization path, may lead to the grouping of RM informants based on homophily 
effects. This may have serious implications for venture outcome, as groups will either randomly 
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all succeed or fail based on whether their interpretation of the best commercialization path was 
accurate or not (Miner et al, 1996). 
 
Institutional culture  
RM venturing is driven by university-led stem cell research, which encourages venturing 
activity to be linked to university research and commercial outcomes. The embedded institutional 
culture and processes at the university and TTO are, therefore, likely to have an imprinting effect 
on the structure and characteristics of RM ventures which emanate from the university 
(Stinchcombe, 1965; Kimberly, 1975). At founding, new ventures are determined by the specific 
technological, economic, political and cultural resources that are available to them (Johnson, 
2007). To ensure their survival and growth, they must follow strategies that are rewarded by their 
external environment (Kriaucinas and Kale, 2006). However, since RM ventures operate under 
extended periods of high levels of uncertainty, it is reasonable to suggest that imprinting effects 
will have unintended outcomes on the survival of young RM ventures. As such, imprinting 
effects, and also the inventing academic-entrepreneur’s prior role-identity conflicts, presents 
significant challenges to RM venturing.  
 
Practical Implications 
Findings of this study present a novel picture of organizational coping under high levels of 
uncertainty. We suggest the need for entrepreneurs and new ventures to adopt coping strategies in 
response to the high levels of PEU, which can result in the development of collaborative 
knowledge and venture development. Entrepreneurs and new ventures, which fail to adhere to 
this, may find themselves unable to develop their business model. 
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Our findings are also especially useful to TTOs, who are charged with: (1) preventing the 
improper use of inventions, (2) boosting financial returns from IP, and (3) generating social 
benefits from university research (Siegel et al, 2004). We recommend that universities and TTOs, 
which expect to commercialize their stem cell research, need to consider balancing their 
academic and commercialization culture. However, given the high uncertainties surrounding RM 
commercialization, the risk–aversive nature of TTOs and their focus on short-term cash 
maximization, commercialization of university-led RM research is still likely to be challenging 
(Phan and Siegel, 2006).  
This research also has implications to UK government policymakers, who are not only 
charged with ensuring that the UK remains at the forefront of RM research, but also with the 
commercialization of this research. Our proposed RM venturing process model provides an 
important contribution in ensuring that the UK exploits the commercialization aspect of RM 
research. 
 
Limitations and Directions for Future Research 
In this study we examined RM venturing under high levels of PEU. We relied on 
informants recounting their involvement in RM venturing through a narrative process and as a 
result, we developed a RM venturing process model. Whilst the results of this study appear to be 
robust, the extent to which the RM process model is a true reflection of the RM venturing field, 
can only be confirmed through empirical analysis that tests specific hypotheses. The inductively 
derived theories of RM venturing proposed in this study also require further testing, refinement 
and development through further empirical research. There are also limitations inherent to our 
dataset, since it is primarily limited to RM venturing informants located in Scotland. Therefore, 
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caution should be exercised in generalizing findings to other geographical or ecosystem 
boundaries. In addition, our dataset contains an overrepresentation of RM support entities. 
Further empirical research is required to provide generalizable results of RM venturing. It 
would be especially useful to extend the small pilot survey to a large survey, which covers an 
international dataset. Furthermore, extension of interviews to other regions of the UK and 
internationally, is warranted.  
We have suggested that RM entrepreneurs and ventures are relying on selective revealing. 
Further research is required to fully understand the existence and role of selective revealing in 
RM venturing, particularly the drivers and outcomes of this alternative form of collaboration 
mechanism. This is consistent with further research calls from Alexy et al (2013) and has the 
potential to reveal if RM ventures selectively reveal knowledge intentionally or unintentionally in 
order to shape the behavior of external actors.  
We call upon further research to reveal the full nature of individual and organizational 
coping responses during opportunity exploitation and under high levels of PEU. This may 
distinguish which coping strategies are useful or detrimental in context. From this we can gain a 
deeper understanding of coping strategies for the assembly of resources, the development of 
collaborative knowledge and venture outcome. Our results emphasize the importance of research 
linking entrepreneurial cognition and decision-making to venture process, especially under high 
levels of uncertainty. 
 
Conclusions 
We investigated entrepreneurial activity within RM venturing, which is a sector 
characterized by unusually high levels of uncertainty. Our study advances theories of venture 
development by proposing a preliminary model linking uncertainty, collaboration and coping. 
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We show that under high levels of PEU, entrepreneurs and RM ventures engage in coping 
strategies for venture development. Coping strategies address the high levels of uncertainty and 
the scarcity of resources, and include collaborations and legitimacy building. These assist 
resource assembly and drive collaborative knowledge development, leading to venture formation 
and growth. Furthermore, we have progressed the understanding of university-industry 
scholarship by showing the potential link between university culture and venture coping 
strategies. 
  
11294	  
	  
26	  
26	  
Tables and Figures 
 
Table 1. Study Informant Information 
Informant 
number 
Informant’s role Category Organization type Organization 
location 
1 Director of 
Operations 
Support entity Services  Edinburgh 
2 Chief Executive 
Officer and Founder 
Entrepreneur Tools/Diagnostics/Services/Cell 
Therapies 
Glasgow 
3 Business 
Development 
Manager 
RM company Services/Research Edinburgh 
4 Chief Executive 
Officer and Founder 
Entrepreneur Services/Research/Consultancy Edinburgh 
5 Academic scientist Academic Scientist Research Edinburgh 
6 Senior Economic 
Development Officer 
Support entity Services  Edinburgh 
7 Chief Executive 
Officer 
Support entity Services Edinburgh 
8 Business 
Development 
Executive 
Support entity Research Edinburgh 
9 Director and 
Academic 
Academic scientist Research Edinburgh 
10 Chief Executive 
Officer and Founder 
Entrepreneur Cell Therapies/Services Manchester  
11 Industry Liaison 
Manager 
Support entity Services  Glasgow 
12 Technology Manager Support entity Services  UK wide 
13 Chief Executive 
Officer and Founder 
Entrepreneur Tools/Diagnostics/Services/Research Edinburgh 
14 Chief Scientific 
Officer and Founder 
Entrepreneur Services Glasgow 
15 Chief Executive 
Officer  
Support entity Cell Therapies/Services/Research  London 
16 Chief Executive 
Officer  
RM company Tools/Diagnostics Royston  
17 Outreach manager Support entity Services Scotland 
18 International Senior 
Executive 
Support entity Services  Scotland 
19 Entrepreneur Entrepreneur Tools/Diagnostics Edinburgh/ 
Glasgow 
20 Chief Executive 
Officer 
Support entity Services Edinburgh 
21 Head of Business 
Development 
Support entity Services/Research Edinburgh 
22 Academic scientist Academic scientist Research Edinburgh 
23 Head of Business 
Creation 
Support entity Services/Research Edinburgh 
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Table 2. Data Structure 
Prevalence in study 
sample (%)* 
First-Order Codes Theoretical Categories Theoretical Dimensions 
Informant categories  
 
T     E     A    SE    RC 
   
61    83    67   50    50 
74    100  67   58    100 
43    33    67   42    50 
 
 
39    50    0     42    50 
17    17    33   17    0 
17    33    0     8      50   
13    17    0     17    0    
 
Risk 
Funding issues 
Manufacturing, scale-up 
and distribution 
uncertainty 
Regulatory uncertainty 
Scientific uncertainty 
Ethics 
Reimbursement 
uncertainty 
Types of uncertainty Perceived 
environmental 
uncertainty (PEU) 
39    17    33   58    0 
39    17    67   50    0 
30    0      67   42    0 
Academic conflicts 
Academic motivations 
Academic metrics 
Inventing entrepreneurs University 
entrepreneurial culture 
35    17    0     58    0   TTO business models and 
processes 
TTO business models and 
processes 
91    83    67   100  100 
 
74    33    100  83   100  
 
39    17    33    50    50 
35    0      33    50    50 
 
Collaborations with 
industry 
Collaborations with 
academia 
Collaborations with NHS 
Collaborations with 
support entities  
Collaborative partners Coping strategies 
39    67    67    17    50 
 
30    17    33    25   100 
 
22    0      67    25    0 
 
9     17     33    0      0 
4     17     0      0      0 
 
Collaboration for sharing 
of resources 
Collaboration for process 
improvement 
Collaboration for funding 
purposes 
Collaboration costs 
Collaboration for 
legitimacy building 
Collaborative outcomes 
61    83    67    58    0 Legitimacy building  Legitimacy building 
57    67    0      67    50 
70    50    100  75    50 
22    50    33    0      50 
26    17    33    33    0 
Knowledge transfer 
Communication 
Learning 
Language differences 
Resource exchange 
mechanisms 
Collaborative 
knowledge 
57    50    33    75    0 RM and scientific 
communities  
Networks 
87    83    67    92   100 
61    83    33    58    50 
35    0      100  33    50 
Governmental funding 
VC funding 
“Big pharma” funding 
Funding sources Venture development 
65    50    67    75    50 Spinout venture 
formation 
Spinout venture formation 
57    100   33   33   100 
9      33     0     0      0 
Business models 
Integrated business model 
Types of RM business 
models 
78    83    100  75    50 Resources Existing resources 
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30    17    33    33    50 
30    0      0      58    0 
Innovation 
Regional investment and 
growth 
Economic development Outcomes 
65    67    67    58   100 
  
9      17    33    0     0 
 
Commercialization 
timeframes 
Potential industry 
structure 
Future scenarios 
* Does not account for multiple occurrences within a single interview. 
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Table 3. Illustrative evidence 
Example Quote 
A “…simply because trying to find funding, I mean, the other issue in all of this is that to undertake 
anything is a hellish expensive process cause, I mean, we aren’t even close to doing anything in terms of 
going into clinical trials, and if you started that realm you're talking mega bucks, and therein lies the big 
challenge for all of us.” (CEO 1, support entity) 
B “And I think the industry is going to be moving to... call it different things: progressive licensing, 
conditional approvals, expanded access, it’s all moving towards this…and again and again the House of 
Lords are talking about conditional approvals and asking people what they think of them, it’s really clear 
that that's going to be how the system moves in the future…So it’s not just doing phase one, two, three, 
get an approval and boom, start marketing. You're marketing it almost... not from day one, but once 
you've got some efficacy, and it’s a gradual increase in exposure to the patients.” (Entrepreneur 3) 
C “The second sort of major group of problems are in what I’d call manufacturing and supply chain 
issues…Lastly of course the major issue, how d'you get live cells to a patient or cells that are preserved 
and delivered to a patient or tissues that have been grown and implied, so the entire business model, 
manufacture and supply chain model is significantly different from what biotech and big pharma 
understands as their business model.” (CEO 2, support entity) 
D “…but you can see where this, you know, is the whole process going to be very much more localized 
than you had with the pharmaceutical industry?” (Entrepreneur 3) 
E “The treatment of the patent regulations in Europe has also sort of blown things a bit in terms of people 
saying ‘well, how do you develop something if you can't protect it?’ you know, that's something else.” 
(CEO 1, support entity) 
F “…now there's no way we’re going to be doing clinical development on our own because we can't afford 
to do it…” (Business Development Manager, RM company) 
G “…reimbursement, that's the bit that's the missing piece at the moment.” (Entrepreneur 3) 
H “Ok, so Neil and I sat down and talked about it and we, we, we had enough money for about another 6 
months or something in the bank and we said we’ve got two choices; we can go find another processing 
partner, we can repair the issue with this processing partner, which was only beginning to unfold at the 
time, or we can do this ourselves, which we always wanted to do but were scared of the cost, the 
implications, weren’t sure if we’d get regulatory approval so that we could commission a lab and try and 
raise money to do that, it's very difficult, it all a catch 22, raising money is a whole big catch 22……em, 
and, eh, so we took a decision to throw all the money at building a facility and doing it ourselves…” 
(Entrepreneur 1) 
I “Well, so yes, so that’s obviously a very difficult area because there’s a tension here isn’t there? I mean 
academics as I’ve already said are judged by their papers and their grants…And, erm, spinouts take a lot 
of time and a huge amount of work, erm, in terms of putting it all together and then a lot of time 
promoting it and I think that group leaders find that extremely difficult because that’s time that they’re 
not doing their academic work and ultimately they will be judged with the current metrics much more on 
their academic work then they will on their commercialization work.” (Academic scientist 2) 
J “I guess again that comes down to their tech transfer department to do that. Again, will they necessarily 
understand? I don't think so?” (Director of Operations, support entity)  
K “…so we have access to the cell lines, or at least some of them, from [company name].” (Business 
Development Manager, RM company) 
L “…the idea is that if we can work with them and take some of the processes and tune them up for proper 
manufacturing.” (CEO 2, support entity) 
M “Access to the NHS is very challenging in Scotland, very challenging indeed and companies often feel 
that they would benefit – and they would benefit – from early conversations with the NHS where before 
they design their medical device, they get input from the end users and that's really challenging… But 
access to the NHS is something that comes up again and again and again, it’s just something that's not 
happened in Scotland.” (Industry Liaison Manager, support entity) 
N “…our processing partner and the processing partner failed the regulatory inspection in a blaze of 
glory…and the, em, the Human Tissue Authority, the regulator, suspended our human tissue authority 
license…” (Entrepreneur 1) 
O “…we had been talking to him, and talking to him, and talking to him, and he didn't, at first, believe that 
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our technology did what it said it did because it is a paradigm shift for stem cell technology…and we get 
a lot of people who don’t believe it, although less and less. We are able to show people stuff now that 
makes them realize that’s it’s the real deal…” (Entrepreneur 1) 
P “The other thing we managed to do is persuade, and this was the key I guess, was to persuade Scottish 
Enterprise that it was in their interest or Scotland's interest in developing the regen medicine to help fund 
the development of this capability….” (CEO 1, support entity)  
Q “…we've become active internationally as a mechanism of trying to demonstrate that UK is an attractive 
place to do this sort of work in and then we’ll partner with potential inward investors to either set up 
manufacturing, you know, get clinical trials done, potentially being, if you like, the entry point into the 
European arena through the UK.” (CEO 2, support entity) 
R “...guess [we have] being able to convince people…they may look back and say ‘right, who let those 
idiots loose’, I don't know [laugh] they may well say that now! But certainly at the time no, they were 
fairly relaxed in terms of, if you like, ‘trusting’ that we knew what we were doing or what we’d like to 
do.” (CEO 1, support entity)  
S “I'm working, as I say, with [name of collaborator] and we are developing techniques which hopefully 
will have commercial applications in the future. So it’s kind of using my communication skills and 
knowledge of embryology and his knowledge of transgenics and how that works.” (Entrepreneur 2) 
T “…so there was a lot of work at that time about creating a network/a community which would almost act 
as the kind of interpreter or teach the others at least some of the key words from their different languages 
so they could at least understand each other when they were talking to each other.” (Director of 
Operations, support entity) 
U “…we had a knowledge transfer partnership with the university… and really that was used to sort of 
develop our capability in creating cell lines that basically took on the form of hepatocytes.” (Senior 
Economic Development Officer, support entity) 
V “So I think, you know, first thing you've got to sit down with medics and properly discuss indication.” 
(Entrepreneur 3) 
W “The two communities are different aren’t they…we speak a different jargon, speak a different 
language.” (Academic scientist 1) 
X “But I did talk to the people in advance and I think this is quite a good thing to do as well is to talk to the 
TSB or whoever is awarding the grant that you're applying for and say ‘look, we’re thinking about doing 
this sort of thing, should we give up already or is this worth doing?’ and I was told it was worth doing.” 
(Business Development Manager, RM company) 
Y “…because at the moment people in regen med talk about a funding gap and you'll hear this from many 
people, but preclinical stuff... this kind of research and development that goes on in the university is 
great, it’s all academic. You then sort of do proof of concept stuff which is fundable because it’s fairly 
cheap, but then there's this clinical development which is extremely expensive and small companies can't 
afford it, universities certainly can't afford it.” (Business Development Manager, RM company) 
Z “So all the funding that we get has to be matched and that's where a lot of people think that it’s very easy 
cause all these grants are available, but nobody’s prepared to take a huge mortgage out to pay for it or to 
pay the matching part because at the end of it they're not sure if they're going to get any money back.” 
(Entrepreneur 4) 
AA “The other part to it which actually to be honest never really materialized, we also thought there was the 
opportunity of people actually utilizing our facilities to undertake that work, for them to actually come in 
and do that work, a bit like a hotel. In reality that bluntly didn't happen for whatever reasons…what we 
did with Cell Lab to some extent is move away... and started to moved away from a company that was... 
you could argue was almost a service company to one that would eventually ‘have product or products’ 
based on IP in one form or another, whether patented or not, that we could then market.” (CEO 1, 
support entity)  
BB “…so we now have Oristem available in 6 countries…Now alongside all of that we have digressed into 
other products as well, so we have, em, actually got four products now. Oristem being the key 
product…And then the final product, erm, is called Thallocell. But also we have two other therapies, em, 
that we’re working on as well. Em, one is an aesthetic medicine, so it’s, em, cosmetics…So we would 
hope to engage in a clinical trial in Hong Kong in the next 6 months, em, with proof of concept first, 
kind of 10 people safety study…the cell type we have is ridiculously cool and, em, we have some 
amazing technology and we’re trying to do so much with it. And then we have another idea which is 
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around cardio, myocardio infarc.” (Entrepreneur 1) 
CC “For renewable energy you can see windmills, you can see things going up, you can see things being 
built, you can see jobs being created, in regenerative medicine you can't see that and the output you 
would argue at the end of that might be that you're going to be using the current academic community, 
the current clinical communities, so the same people, not particularly new jobs created which is what 
they're all interested in; the output is when patients start getting better and the NHS costs go down.” 
(Director of Operations, support entity)  
DD “I think it’s just that complete dyssynchrony between the timescales involved for this and the timescales 
of most investors, even kind of public sector investors in this; they just can't wait that length of time and 
I guess even if you get... what we’re beginning to get the impression that kind of regenerative medicine 
is beginning to lose its appeal even at Government level in Scotland now, just because there's nothing 
you can see for it.” (Director of Operations, support entity) 
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Figure 1. Informants’ Level of Agreement with Particular Statements 
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Figure 2. Revealed significance of uncertainty during narrative interview 
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Figure 3. Process Model of RM Venturing 
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